<DOC>
	<DOC>NCT01806337</DOC>
	<brief_summary>Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation</brief_summary>
	<brief_title>CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Peripheral T cell lymphoma patients of all subtypes according to WHO are treated with an induction of 6 cycles of CHOP-etoposide-14 (if below 60 years of age) oder CHOP-14. If at least a PR is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>all risk groups in international prognostic index diagnosis of aggressive Tcelllymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment. these lymphomas comprise: peripheral Tcell lymphoma PTCLNOS LennertÂ´s lymphoma Tzone lymphoma angioimmunoblastic Tcelllymphoma Performance status: ECOG (Eastern Cooperative Oncology Group Score) 03(Karnofsky index 40100%) written consent of the patient Declaration of center participation Already initiated lymphoma therapy(exept for the prephase treatment specified for this study) Serious accompanying disorder or impaired organ function bone marrow involvement&gt;25% Known hypersensitivity to medications to be used Know HIVpositivity Active hepatitis infection, active CMV infection, prior florid tuberculosis floride systemic infections suspicion that patient compliance will be poor Simultaneous participation in any the study protocol prior chemoor radiotherapy for malignancy other concomitant malignant disease Pregnancy or lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>peripheral T cell lymphoma</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>consolidation</keyword>
</DOC>